Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
Retrieved on:
Monday, December 12, 2022
Life, Gates Cambridge Scholarship, Quality of life, Oropharyngeal cancer, National university, Security (finance), Lymphatic system, Doxorubicin, CSI, DNA, Cancer, Mucositis, Gene expression, ASH, NUS, MD, National University of Singapore, Immanuel Congregation (CSI), Singapore, Gene, Research, Society, Apoptosis, Therapy, DDR, COVID-19, Patient, Drug resistance, Pharmaceutical industry, Vaccine
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).
Key Points:
- WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS).
- Monopar has made the poster available on its website at the following link: https://www.monopartx.com/pipeline/mnpr-202 .
- MNPR-202 is a promising DNA Damaging Response (DDR) drug candidate, and analog of doxorubicin.
- Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.